Extract
In patients with COPD, blood eosinophil counts can predict the effects of inhaled corticosteroids (ICS) on exacerbation rates [1–4]. Blood eosinophil counts are now recommended by the Global initiative for the management of Obstructive Lung Disease (GOLD) as a biomarker to help guide ICS use in clinical practice [5].
Abstract
Blood eosinophil counts are increased in COPD patients compared to healthy controls http://bit.ly/2ML6pzZ
Footnotes
Conflict of interest: U. Kolsum has nothing to disclose.
Conflict of interest: T. Southworth is an employee of the Medicines Evaluation Unit.
Conflict of interest: N. Jackson has nothing to disclose.
Conflict of interest: D. Singh reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Glenmark, Menarini, Mundipharma, Novartis, Pfizer, Pulmatrix, Therevance and Verona, and personal fees from Cipla, Genentech and Peptinnovate, outside the submitted work.
Support statement: D. Singh is supported by the NIHR Manchester BRC
- Received March 29, 2019.
- Accepted June 9, 2019.
- Copyright ©ERS 2019
INDIVIDUALS
Log in using your username and password
LIBRARY USERS
Log in through your institution
Purchase access
CONTACT US
If you have any questions about the ERS publications website, please contact journals@ersnet.org
